Compare prices and buy peptides in the GLP Agonist & Weight Loss category from every research peptide vendor, supplier and source we index. Updated daily.
GLP-1 and multi-receptor agonists behind the modern obesity and diabetes wave (semaglutide, tirzepatide, retatrutide), plus metabolic compounds catalogued alongside them.
GLP-1 (glucagon-like peptide-1) is an endogenous incretin hormone released by L-cells in the small intestine after a meal. It stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on brain regions that regulate appetite. Native GLP-1 is degraded by DPP-4 within minutes, whereas synthetic receptor agonists resist that cleavage and last far longer in circulation.
Semaglutide is approved as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management.
The category now extends well past single-receptor agonism, and each added receptor axis contributes an independent mechanism.
Vendors also sell blends. Semaglutide + cagrilintide pairs the two molecules Novo Nordisk tested together as CagriSema, while retatrutide + cagrilintide and retatrutide + tirzepatide have no clinical trial counterpart.
Approval status varies sharply within this category. Semaglutide, tirzepatide and orforglipron are FDA-approved and available by prescription. Teduglutide is approved as Gattex for short bowel syndrome. Innovent reports approvals for mazdutide in China, and it holds no FDA approval. Retatrutide, survodutide, cagrilintide and eloralintide are investigational, with no FDA approval as of October 2026.
Research-peptide vendors sell lyophilized powders under brand-agnostic INN names, developer codes, or their own shorthand. Two conventions dominate.
Our post on what GLP-3 means explains how to read these codes and where they mislead.
Three non-GLP metabolic research tools are grouped here for catalog convenience rather than shared mechanism. AOD-9604 is a synthetic analog of the C-terminal end of human growth hormone. AICAR is an AMPK activator studied for endurance and metabolic adaptation, and appears on the World Anti-Doping Agency prohibited list. Lipo-C is a lipotropic injection blend whose formulation varies by vendor.
Most research-peptide vendors use GLP-N as a generational product code rather than a scientific class name. In that convention GLP1 is semaglutide, GLP2 is tirzepatide, and GLP3 is retatrutide, numbered by drug generation. This conflicts with scientific naming, where GLP-2 is a separate hormone whose approved analog is teduglutide. At least one vendor has used the literal scientific convention, so a listing labelled GLP2 can be either tirzepatide or teduglutide depending on the seller. PeptideScouter assigns a vendor code to a compound only after checking its published CAS number or molecular formula, so the same compound lands on the same page regardless of how a vendor codes it.
Semaglutide (as Ozempic, Rybelsus and Wegovy), tirzepatide (as Mounjaro and Zepbound) and orforglipron (as Foundayo) are FDA-approved prescription medicines. Teduglutide is approved as Gattex for short bowel syndrome. Mazdutide is approved in China, according to its developer Innovent, but not by the FDA. Retatrutide, survodutide, cagrilintide and eloralintide are investigational, with no FDA approval as of October 2026. Approval status refers to the licensed pharmaceutical product. Research-grade material sold by the vendors indexed here is not a licensed medicine and is labelled for laboratory research only.
Single agonists such as semaglutide activate only the GLP-1 receptor. Dual agonists add a second target: tirzepatide adds GIP, while survodutide and mazdutide add the glucagon receptor. Retatrutide is a triple agonist covering GLP-1, GIP and glucagon. GIP is a second incretin hormone, and nonclinical studies suggest its receptor adds to the regulation of food intake. In studies in obese mice, glucagon-receptor activity added an increase in energy expenditure to reduced calorie intake.
No. Orforglipron (Eli Lilly, developer code LY3502970) is a non-peptide small molecule that activates the GLP-1 receptor and is taken orally, unlike most of the peptide agonists it is grouped with. It is catalogued in this category because it targets the same receptor and competes in the same therapeutic space, but it is chemically a different class of drug, not a lyophilized peptide powder.
47 vendors tracked by PeptideScouter sell GLP Agonist & Weight Loss peptides, across 860 listings covering 15 compounds. The widest GLP Agonist & Weight Loss catalogs belong to Flawless Compounds (13 peptides), Glow Aminos (13 peptides), Iron Protocol (13 peptides). Prices are normalized to USD per milligram and refreshed daily.
GLP Agonist & Weight Loss peptides indexed on PeptideScouter have a median price of $6.82/mg, ranging from $0.16/mg to $11.97/mg across the 15 peptides in the category. Pricing is normalized across vendors and refreshed daily.
Lipo-C carries the lowest median price in the GLP Agonist & Weight Loss category at $0.16/mg across 25 listings. Its cheapest in-stock listing is $0.10/mg at Studz Peptides. Per-milligram price varies widely between compounds in a category, so the cheapest per mg is not necessarily the cheapest vial or the right compound for a given experiment.
The most widely sold GLP Agonist & Weight Loss peptides on PeptideScouter (by vendor count) are: Retatrutide, Tirzepatide, Semaglutide, Cagrilintide, AOD-9604. Each peptide page shows current pricing across every tracked vendor, normalized to USD per milligram.
